TY - JOUR
T1 - Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic/Myeloproliferative Neoplasms-Unclassifiable
T2 - A Retrospective Nationwide Study of the Japan Society for Hematopoietic Cell Transplantation
AU - Kurosawa, Shuhei
AU - Shimomura, Yoshimitsu
AU - Tachibana, Takayoshi
AU - Ishiyama, Ken
AU - Ota, Shuichi
AU - Kobayashi, Takeshi
AU - Uchida, Naoyuki
AU - Fukushima, Kentaro
AU - Ashida, Takashi
AU - Matsuoka, Ken ichi
AU - Kanda, Junya
AU - Ichinohe, Tatsuo
AU - Atsuta, Yoshiko
AU - Murata, Makoto
AU - Aoki, Jun
N1 - Funding Information:
The authors are grateful to all physicians and staff at the transplantation centers who contributed to the collection of data for the Transplant Registry Unified Management Program of the Japan Society of Hematopoietic Cell Transplantation. Financial disclosure:, Conflict of interest statement: There are no conflicts of interest to report. Financial disclosure: See Acknowledgments on page 1610.
Publisher Copyright:
© 2020 American Society for Transplantation and Cellular Therapy
PY - 2020/9
Y1 - 2020/9
N2 - To date, there are no data focusing on outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN-U). This study aimed to evaluate outcomes and prognostic factors in patients with MDS/MPN-U after allo-HSCT using Japanese nationwide registry data. The primary endpoint was 3-year overall survival (OS); secondary endpoints included the cumulative incidence of relapse and nonrelapse mortality (NRM). We evaluated the prognostic factors for 3-year OS by univariate analysis using the log-rank test. In our cohort of 86 patients with MDS/MPN-U, we found a 3-year OS of 48.5%, cumulative incidence of relapse of 23.7%, and NRM of 26.3%. The 3-year OS was significantly worse in patients age ≥50 years compared with those age <50 years (38.1% versus 65.0%; P = .049) and in patients with disease progression compared with those without disease progression (28.4% versus 57.2%; P = .042). Our results suggest that allo-HSCT may offer a curative option for patients with MDS/MPN-U, and that age and disease status could be important indicators in helping clinicians determine treatment options for these patients.
AB - To date, there are no data focusing on outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN-U). This study aimed to evaluate outcomes and prognostic factors in patients with MDS/MPN-U after allo-HSCT using Japanese nationwide registry data. The primary endpoint was 3-year overall survival (OS); secondary endpoints included the cumulative incidence of relapse and nonrelapse mortality (NRM). We evaluated the prognostic factors for 3-year OS by univariate analysis using the log-rank test. In our cohort of 86 patients with MDS/MPN-U, we found a 3-year OS of 48.5%, cumulative incidence of relapse of 23.7%, and NRM of 26.3%. The 3-year OS was significantly worse in patients age ≥50 years compared with those age <50 years (38.1% versus 65.0%; P = .049) and in patients with disease progression compared with those without disease progression (28.4% versus 57.2%; P = .042). Our results suggest that allo-HSCT may offer a curative option for patients with MDS/MPN-U, and that age and disease status could be important indicators in helping clinicians determine treatment options for these patients.
KW - Allogeneic hematopoietic stem cell transplantation
KW - Myelodysplastic/myeloproliferative neoplasms, unclassifiable
UR - http://www.scopus.com/inward/record.url?scp=85086700592&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086700592&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2020.05.013
DO - 10.1016/j.bbmt.2020.05.013
M3 - Article
C2 - 32454216
AN - SCOPUS:85086700592
SN - 1083-8791
VL - 26
SP - 1607
EP - 1611
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 9
ER -